[B domain mutations in the polymerase gene of hepatitis B virus during combination therapy with thymosin alpha1 and famciclovir in Chinese asymptomatic HBV carriers].
Hou. J J; Wang. Z Z; Sun. J J
Key Findings
- B domain
- These B‑domain mutations were associated with a rebound in HBV DNA levels during treatment.
- The mutations clustered in the B domain rather than the classic YMDD motif of the polymerase gene.
Practical Outcomes
- For biohackers or self‑experimenters, this study offers no actionable insight for longevity, metabolic health, or performance. It simply warns that combining thymosin‑alpha‑1 with famciclovir in HBV carriers may promote viral resistance, a scenario unlikely to be relevant to most health‑optimization protocols.
Summary
In a study of Chinese people with silent hepatitis B, adding the peptide thymosin‑alpha‑1 to the antiviral drug famciclovir caused genetic changes in the virus that were linked to the virus bouncing back, while thymosin‑alpha‑1 alone did not cause these changes.
Abstract
To identify 'B domain' mutations of polymerase gene and its relationship with drug resistance during treatment with famciclovir in Chinese chronic asymptomatic HBV carriers. Sequential sera from 29 Chinese chronic HBeAg positive HBV carriers treated with combination therapy with thymosin alpha1 (Talpha1) plus famciclovir and also from 15 cases treated with Talpha1 alone, were studied. Nucleotide sequences encoding 'B' and 'C domain' of the HBV polymerase gene were determined by direct or cloning sequencing methods. Nine Talpha1 plus FCV-treated and none of the Talpha1 treated patients developed mutations in the 'B domain' of polymerase gene which could result in amino acid changes. The development of 'B domain' mutations, during treatment, was significantly associated with HBV DNA rebound in those who received Talpha1 plus FCV. Mutations in FCV-treated patients resulting in amino acid changes mainly cluster in the 'B domain' of polymerase gene rather than in YMDD motif. The presence of mutations is significantly associated with HBV DNA rebound during treatment.
Study Information
pubmed
2000